{"id":948596,"date":"2026-04-02T07:40:46","date_gmt":"2026-04-02T11:40:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-clinical-collaboration-with-incyte-to-evaluate-muzastotug-adg126-in-combination-with-incytes-tgfsr2xpd-1-bispecific-antibody-inca33890-in-patients-with-microsatellite-st\/"},"modified":"2026-04-02T07:40:46","modified_gmt":"2026-04-02T11:40:46","slug":"adagene-announces-clinical-collaboration-with-incyte-to-evaluate-muzastotug-adg126-in-combination-with-incytes-tgfsr2xpd-1-bispecific-antibody-inca33890-in-patients-with-microsatellite-st","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-clinical-collaboration-with-incyte-to-evaluate-muzastotug-adg126-in-combination-with-incytes-tgfsr2xpd-1-bispecific-antibody-inca33890-in-patients-with-microsatellite-st\/","title":{"rendered":"Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte\u2019s TGF\u00dfR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)"},"content":{"rendered":"
\n

\n Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients<\/em>
\n with and without liver metastases <\/em>\n <\/p>\n

\n Study will be sponsored and conducted by Incyte; Adagene to provide clinical supply of muzastotug<\/em>\n <\/p>\n

\n Collaboration provides additional validation of muzastotug as a potential backbone therapy for next-generation immuno-oncology combinations<\/em>\n <\/p>\n

SAN DIEGO and SUZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a clinical collaboration with Incyte (Nasdaq:INCY), to evaluate the combination of muzastotug (ADG126) and INCA33890, a TGF\u03b2R2 \u00d7 PD-1 bispecific antibody, in patients with microsatellite stable colorectal cancer (MSS CRC) with or without liver metastases.<\/p>\n

Muzastotug in combination with Merck\u2019s (known as MSD outside of the United States and Canada) anti-PD-1 therapy, KEYTRUDA\u00ae\u00a0(pembrolizumab) has demonstrated encouraging overall response rates and durable responses in a Phase 1b\/2 trial in 3L MSS CRC patients. As a monotherapy, INCA33890 has demonstrated promising clinical efficacy and safety in immune checkpoint sensitive and insensitive cancers, including MSS CRC with and without liver metastases. Incyte has recently initiated a Phase 3 study (NCT07284849<\/a>) evaluating bevacizumab and FOLFOX (standard of care chemotherapy) with or without INCA33890 in 700 first-line MSS CRC patients.<\/p>\n

\u201cThis strategic collaboration marks the second instance in which Adagene\u2019s SAFEbody\u00ae technology is being paired with a leading PD-1\u2013based bispecific, further reinforcing muzastotug\u2019s potential as a backbone immunotherapy with a wider therapeutic index for next-generation immuno-oncology combinations,\u201d said Peter Luo, Ph.D., CEO and President of R&D at Adagene. \u201cWe look forward to the clinical insights this study may provide to support our belief that muzastotug has the potential to both improve overall response rate and extend survival, meaningfully enhancing the clinical benefit for patients.\u201d<\/p>\n

\u201cThis collaboration allows us to explore a novel combination approach for patients with microsatellite stable colorectal cancer, a disease that remains resistant to current immunotherapies,\u201d said Pablo J. Cagnoni, M.D., President, Head of Research & Development at Incyte. \u201cBy evaluating INCA33890 in combination with muzastotug, we aim to better understand whether complementary mechanisms may help enhance anti-tumor immune responses particularly for patients with liver metastases, who have an especially poor prognosis and limited treatment options.\u201d<\/p>\n

Muzastotug, a masked anti-CTLA-4 SAFEbody\u00ae with FDA Fast Track designation, is currently being evaluated in multiple ongoing studies, including:<\/p>\n